6-phenylpteridine-2,4,7-triamine

• ChemBase编号: 268
• 分子式: C12H11N7
• 平均质量: 253.26264
• 单一同位素质量: 253.10759339
• SMILES: n1c(c2ccccc2)c(nc2nc(nc(N)c12)N)N
• Canonical SMILES: Nc1nc(N)c2c(n1)nc(c(n2)c1ccccc1)N
• InChI: InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
• InChIKey: FNYLWPVRPXGIIP-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 6-phenylpteridine-2,4,7-triamine
• IUPAC传统名: triamterene; 6-phenylpteridine-2,4,7-triamine
• 商标名: Ademin; Ademine; Diren; Ditak; Diucelpin; Diurene; Dyazide; Dyren; Dyrenium; Dytac; Jatropur; Maxzide; Maxzide-25; Noridil; Noridyl; Pterofen; Pterophene; Taturil; Teriam; Teridin; Tri-Span; Triampur; Triamteril; Triamteril Complex; Trispan; Triteren; Urocaudal
• 别名: 2,4,7-三氨基-6-苯基蝶啶; 6-PHENYL-2,4,7-TRIAMINO PTERIDINE; 6-Phenyl-2,4,7-pteridinetriamine; Triamterene; 6-Phenyl-2,4,7-triaminopteridine; Ademin; Ademine; Diren; Ditak; Diurene; NSC 77625; Noridil; Triamterene; 2,4,7-Triamino-6-phenylpteridine; Triamteren; Triamterene; 6-Phenyl-2,4,7-pteridinetriamine; 2,4,7-Triamino-6-phenylpteridine; urocaudal; Dytac; Dyrenium; Jatropur; Triampur; Tri-Span; Adernine; Pterofen; Pterophene; Triteren; 6-phenylpteridine-2,4,7-triamine

登记号

• CAS号: 396-01-0
• EC号: 200-659-6; 206-904-3
• MDL号: MFCD00006708
• Beilstein号: 266723
• 默克索引号: 149599
• PubChem SID: 24277877; 46507623; 160963731
• PubChem CID: 5546

理论计算性质

JChem

• Acid pKa: 15.8762245
• 质子受体: 7
• 质子供体: 3
• LogD (pH = 5.5): 1.114474
• LogD (pH = 7.4): 1.1145703
• Log P: 1.1145715
• 摩尔折射率: 75.1259 cm^3
• 极化性: 27.961065 Å^3
• 极化表面积: 129.62 Å^2
• 可自由旋转的化学键: 1
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.21
• LOG S: -2.42
• 溶解度: 9.63e-01 g/l

分子性质

理化性质

• 溶解度: 48.2 mg/L; DMSO
• 外观: Yellow Solid
• 熔点: >300°C; >300°C (dec.); 316°C
• 闪点: 11 °C; 51.8 °F
• 疏水性(logP): -0.247; 0.3

安全信息

• 保存条件: -20°C Freezer; Room Temperature (15-30°C)
• 保存注意事项: IRRITANT
• RTECS编号: UO3470000
• 欧盟危险性物质标志: 易燃性(Flammable) (F); 有毒(Toxic) (T); X; 有害性(Harmful) (Xn)
• 联合国危险货物编号: 1230
• 德国WGK号: 1; 3
• 联合国危险货物等级: 3
• 联合国危险货物包装类别(PG): 2
• 危险公开号: 11-23/24/25-39/23/24/25; 22-36/37/38; R:22
• 安全公开号: 26-36/37; 26-36/37/39; 7-16-36/37-45; S:36/37/39
• TSCA收录: false; 否
• GHS危险品标识: GHS02; GHS06; GHS07; GHS08
• GHS警示词: Danger; Warning
• GHS危险声明: H225-H301-H311-H331-H370; H301-H315-H319-H335; H302-H315-H319-H335
• GHS警示性声明: P210-P260-P280-P301 + P310-P311; P261-P301+P310-P305+P351+P338-P302+P352-P405-P501A; P261-P305 + P351 + P338
• 个人保护装置: dust mask type N95 (US), Eyeshields, Faceshields, Gloves; Eyeshields, Faceshields, full-face respirator (US), Gloves, multi-purpose combination respirator cartridge (US)
• RID/ADR: UN 1230 3/PG 2

药理学性质

• 作用靶点: Sodium Channel
• 生物活性机理: Potassium transport inhibitor; Sodium reabsorption inhibitor; Sodium transport inhibitor

产品相关信息

• 纯度: ≥99%; 95%; 98%
• 成盐信息: Free Base
• 应用领域: Antimalarial agent; Diuretic

详细说明

MP Biomedicals - 05221529

MP Biomedicals Rare Chemical collection

MP Biomedicals - 02156960

Purity: 98%
Sodium channel blocker.

DrugBank - DB00384

• Drug Groups: approved
• Description: A pteridine that is used as a mild diuretic. [PubChem]
• Indication: For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.
• Pharmacology: Triamterene, a relatively weak, potassium-sparing diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene is similar in action to amiloride but, unlike amiloride, increases the urinary excretion of magnesium.
• Toxicity: In the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD₅₀ in mice is 380 mg/kg.
• Affected Organisms: Humans and other mammals
• Biotransformation: Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels.
• Absorption: Rapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine.
• Half Life: 255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.
• Protein Binding: 55-67% (93% for the OH-TA-ester metabolite)
• Clearance: * 4.5 l/min [total plasma clearance]; * 0.22 l/kg [renal plasma clearance]
• References: WellSpring Pharmaceutical Corporation. Dyrenium (triamterene) capsules prescribing information. Neptune, NJ; 2001 June.; Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, Volger KD: Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol. 1983;25(2):237-41. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

Sigma Aldrich - T4143

Biochem/physiol Actions
Weak diuretic with potassium sparing properties; blocks Na+ reuptake in the kidneys.

Toronto Research Chemicals - T767325

Triamterene is a weak diuretic with potassium sparing properties; blocks Na+ reuptake in the kidneys.

参考文献

• WellSpring Pharmaceutical Corporation. Dyrenium (triamterene) capsules prescribing information. Neptune, NJ; 2001 June.
• Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, Volger KD: Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol. 1983;25(2):237-41. Pubmed
• Osdene, et al.: J. Med. Chem., 10, 431 (1967)
• Kapoor, V.K., et al.: Anal. Profiles Drug Subs. Excip., 23, 571 (1967)
• Aldrich Library of Infrared Spectra, 3rd edn., 1981, 1414F, (ir)
• Spickett, R.G.W. et al., J.C.S., 1954, 2887, (synth)
• Pachter, I.J., J.O.C., 1963, 28, 1191, (synth)
• Osdene, T.S. et al., J. Med. Chem., 1967, 10, 431, (synth, pharmacol)
• Fales, H.M. et al., Arch. Mass Spectral Data, 1971, 2, 690, (ms)
• Yamamoto, H. et al., Chem. Ber., 1973, 106, 3175
• Knau, F.H. et al., Arzneim.-Forsch., 1978, 28, 1414, (metab)
• Gundert-Remy, U. et al., Eur. J. Clin. Pharmacol., 1979, 16, 39, (pharmacol)
• Soergel, F. et al., Clin. Pharmacol. Ther. (St. Louis), 1985, 38, 306, (pharmacokinet)
• Schwalbe, C.H. et al., Acta Cryst. C, 1987, 43, 1097, (cryst struct)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 2248
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 829
• Kapoor, V.K., Anal. Profiles Drug Subst., 1994, 23, 571, (rev)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, UVJ450